ABSTRACT:
Promethazine hydrochloride is an antihistamine, antiemetic, and first-generation H1 receptor antagonist that also has potent sedative properties. Topical H1R/2R antagonists' apparent capacity to target epidermal H1/2R was translated into improved therapeutic efficacy for inflammatory dermatoses, most likely as a result of improved barrier function and reduced inflammation.In addition to preventing motion sickness, it is used to treat post-operative nausea and vomiting, as a sedative or sleep aid, particularly for cancer patients, and to treat allergic symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes. The administration of promethazine intramuscularly (25mg) or orally (25 to 50mg) results in peak plasma concentrations after 2 to 3hours. Due to its strong sedative effects, PM is frequently administered at night to alleviate allergy symptoms. Promethazine has also been used to treat allergic reactions and drug hypersensitivity reactions, particularly in emergency situations. Age, gender, genetic polymorphisms, certain viral infections, and medication-related characteristics (e.g., frequency of exposure, mode of administration, and molecular weight) are all linked to an elevated chance of developing a drug allergy. PM has frequently been linked to photosensitivity reactions among its various topically applied uses. Its chemical structure and the range of chemical reactions that result in the phototoxic effects may be responsible for the increased frequency of such negative reactions.
Cite this article:
Neha Chandrashekhar Patil, Sunila A. Patil, Amruta N. Patil. A Brief Review on Promethazine. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(3):329-4. doi: 10.52711/2231-5659.2025.00048
Cite(Electronic):
Neha Chandrashekhar Patil, Sunila A. Patil, Amruta N. Patil. A Brief Review on Promethazine. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(3):329-4. doi: 10.52711/2231-5659.2025.00048 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-3-15
REFERENCES:
1. Patel T. and Yosipovitch G. The management of chronic pruritus in the elderly. Skin Therapy Letter. 2010; 15(8): 5–9.
2. Khan D. A. and Solensky R. Drug allergy. Journal of Allergy and Clinical Immunology. 2010; 125(2): S126–S137.
3. Ashmawi H. A., Braun L. M., Sousa A. M., and Posso I. D. P. Analgesic effects of H1 receptor antagonists in the rat model of formalin-induced pain. Revista Brasileira de Anestesiologia. 2009; 59(4): 461–470. https://doi.org/10.1590/S0034-70942009000400008.
4. Danarti R., Waskito F., and Indrastuti N. Onset and duration of action of topical antihistamine: a study of histamine skin test response. International Journal of Dermatology. 2008; 47(8); 861–863 https://doi.org/10.1111/j.1365-4632.2008.03639.x
5. Yanai K. Anticholinergic activity of antihistamines. Clinical Neurophysiology. 2012; 123(4): 633–634 https://doi.org/10.1016/j.clinph.2011.09.005.
6. Tarkkila P., Torn K., Tuominen M., and Lindgren L. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiologica Scandinavica. 1995; 39(7): 983–986.
7. Scherl E. R. and Wilson J. F. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995; 35(5): 256–259 https://doi.org/10.1111/j.1526-4610.1995.hed3505256.x.
8. Buzdar A. U., Esparza L., Natale R., Cody R., Calzone K., Benson A. B., Sheehan T., and Berry W. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine: a placebo-controlled study. American Journal of Clinical Oncology. 1994; 17(5): 417–421.
9. Lackner J. R. and Graybiel A. Use of promethazine to hasten adaptation to provocative motion. Journal of Clinical Pharmacology. 1994; 34(6); 644–648.
10. Terndrup T. E., Dire D. J., Madden C. M., Davis H., Cantor R. M., and Gavula D. P. A prospective analysis of intramuscular meperidine, promethazine, and chlorpromazine in pediatric emergency department patients. Annals of Emergency Medicine. 1991; 20(1): 31–35, https://doi.org/10.1016/S0196-0644(05)81114-X.
11. Lin T. K., Man M. Q., Santiago J. L., Park K., Roelandt T., Oda Y., Hupe M., Crumrine D., Lee H. J., Gschwandtner M., Thyssen J. P., Trullas C., Tschachler E., Feingold K. R., and Elias P. M. Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. Journal of Investigative Dermatology. 2013; 133(2): 469–478.
12. Ljubojević S. and Lipozencić J. Reactions to insect stings and bites. Acta Medica Croatica. 2011; 65(2): 137–139.
13. Blaya B., Nicolau-Galmés F., Jangi S. M., Ortega-Martínez I., Alonso-Tejerina E., Burgos-Bretones J., Pérez-Yarza G., Asumendi A., and Boyano M. D. Histamine and histamine receptor antagonists in cancer biology. Inflammation and Allergy—Drug Targets. 2010; 9(3): 146–157.
14. Vidal Pan C., González Quintela A., Galdos Anuncibay P., and Mateo Vic J. Topical promethazine intoxication. Current Medical Research and Opinion. 2012; 28(4): 623–642.
15. Yanai K. Anticholinergic activity of antihistamines. Clinical Neurophysiology. 2012; 123(4): 633–634. https://doi.org/10.1016/j.clinph.2011.09.005
16. Wang X.C., Hong J.G., and Yang X.Q. Discussions on the use of promethazine. Chinese Journal of Pediatrics. 2010; 48(7): 557–558.
17. Promethazine should not be used for infants. Pharmazie. 2010; 65(5): 339–342.
18. Al Khaja K. A. J., Al Ansari T. M., Damanhori A. H. H., and Sequeira R. P. Evaluation of drug utilization and prescribing errors in infants: a primary care prescription-based study. Health Policy. 2007; 81(2-3): 350–357, https://doi.org/10.1016/j.healthpol.2006.07.001.
19. Cohen M. R. Frequency and severity of promethazine adverse event reports obligated the ISMP alert. Joint Commission Journal on Quality and Patient Safety. 2010; 36(3): 143–144.
20. Lazarou J., Pomeranz B. H., and Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. Journal of the American Medical Association. 1998; 279(15): 1200–1205, https://doi.org/10.1001/jama.279.15.1200
21. Gandhi T. K., Weingart S. N., Borus J., Seger A. C., Peterson J., Burdick E., Seger D. L., Shu K., Federico F., Leape L. L., and Bates D. W. Adverse drug events in ambulatory care. The New England Journal of Medicine. 2003; 348(16): 1556–1564 https://doi.org/10.1056/NEJMsa020703.
22. Vervloet D. and Durham S. ABC of allergies: adverse reactions to drugs. British Medical Journal. 1998; 316(7143): 1511–1514.
23. Sylvia L. M., J. E. Tisdale and D. A. Miller. Drug allergy, pseudoallergy, and cutaneous diseases, Drug-Induced Diseases: Prevention, Detection, and Management, 2010, 2nd edition, American Society of Health-System Pharmacists, Bethesda, Md, USA
24. Riedl M. A. and Casillas A. M. Adverse drug reactions: types and treatment options. American Family Physician. 2003; 68(9): 1781–1790.
25. Gell P. G. H. and Coombs R. R. A. Clinical Aspects of Immunology, 1975, 3rd edition, Blackwell Scientific, Oxford, UK.
26. Pichler W. J. Delayed drug hypersensitivity reactions. Annals of Internal Medicine. 2003; 139(8): 683–I46.
27. Posadas S. J. and Pichler W. J. Delayed drug hypersensitivity reactions—new concepts. Clinical and Experimental Allergy. 2007; 37(7): 989–999, https://doi.org/10.1111/j.1365-2222.2007.02742.x.
28. Friedmann P. S. and Ardern-Jones M. Patch testing in drug allergy. Current Opinion in Allergy and Clinical Immunology. 2010; 10: 291–296.
29. Schnyder B. Approach to the patient with drug allergy. Immunology and Allergy Clinics of North America. 2009; 29: 405–418.
30. Barranco P. and López-Serrano M. C. General and epidemiological aspects of allergic drug reactions. Clinical and Experimental Allergy. 1998; 28(supplement 4): 61–62.
31. Adkinson N. F. Risk factors for drug allergy. Journal of Allergy and Clinical Immunology. 1984; 74(4): 567–572.
32. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005; 209(2): 209–216 https://doi.org/10.1016/j.tox.2004.12.024.